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TendonTendinopathies are a range of diseases characterised by degeneration and chronic tendon pain and represent
a signiﬁcant cause of morbidity. Relatively little is known about the underlying mechanisms; however
onset is often associated with physical activity. A number of molecular changes have been documented in
tendinopathy such as a decrease in overall collagen content, increased extracellular matrix turnover and pro-
tease activity. Metalloproteinases are involved in the homeostasis of the extracellular matrix and expression
is regulated by mechanical strain. The aims of this study were to determine the effects of strain upon matrix
turnover by measuring metalloproteinase and matrix gene expression and to elucidate the mechanism of ac-
tion. Primary Human Achilles tenocytes were seeded in type I rat tail collagen gels in a Flexcell™ tissue train
system and subjected to 5% cyclic uniaxial strain at 1 Hz for 48 h. TGFβ1 and TGFβRI inhibitor were added to
selected cultures. RNA was measured using qRT-PCR and TGFβ protein levels were determined using a cell
based luciferase assay. We observed that mechanical strain regulated the mRNA levels of multiple protease
and matrix genes anabolically, and this regulation mirrored that seen with TGFβ stimulation alone. We
have also demonstrated that the inhibition of the TGFβ signalling pathway abrogated the strain induced
changes in mRNA and that TGFβ activation, rather than gene expression, was increased with mechanical
strain. We concluded that TGFβ activation plays an important role in mechanotransduction. Targeting this
pathway may have its place in the treatment of tendinopathy.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Tendinopathies are a range of diseases which are characterised by
chronic tendon pain, swelling, localised tenderness, impaired move-
ment, rupture and insidious degeneration of the tendon ECM [1–3].
They are a signiﬁcant cause ofmorbidity and represent a sizable propor-
tion of referrals to general practitioners [4,5]. Relatively little is known
about the underlying mechanisms; however onset is often associated
with an increase in age and physical activity [1,4]. Tendons predomi-
nantly affected are those exposed to higher levels of mechanical strain
such as the supraspinatus, Achilles, patella and posterior tibialis tendon
[3,6]. Althoughprevalent in the ageing general population, younger ath-
letes also commonly affected. This is illustrated by the high incidence of
Achilles tendinopathy runners [1,6]. However, due to our inadequate
understanding of the disease pathology, treatment is restricted to pain
relief, exercise, cryotherapy, non-steroidal ant-inﬂammatory drugs
and surgery [1,3], all of which are often ineffective [1,7,8]. Even afterces, University of East Anglia,
.
s).
B.V. Open access under CC BY license.corrective surgery only 60–85% of patients are able to return to sporting
exercise [6]. In order to develop effective treatments we must ﬁrst un-
derstand the aetiopathology of the disease.
A number of cell and molecular changes have been documented in
tendinopathy such as: a decrease in type I and overall collagen content
and an increase in collagen type III [9,10], increased levels of proteogly-
cans [11–15], increased ECM turnover and protease activity [16] and
changes in cellularity [17]. An increase in Transforming Growth Factor
β (TGFβ) protein has also been reported [18,19]. TGFβ is a cytokine
that (in humans) exists in three isoforms (TGFβ1, TGFβ2 and TGFβ3),
which are involved in many cell processes including cell proliferation,
differentiation and apoptosis [20]. Newly synthesised TGFβ protein
contains a propeptide known as the latency associated peptide (LAP).
In the trans-golgi network, post-translational modiﬁcations involve
cleavage of LAP by proprotein convertase furin [21]. TGFβ and LAP re-
main non-covalently bound rendering TGFβ inactive [22]. However
this inhibition of TGFβ by LAP is not yet fully understood. Latent TGFβ
binding proteins (LTBP) form cysteine disulphide linkages with TGFβ
homodimers via LAP, to form the Large Latent Complex (LLC) [23,24].
LTBP is important in the secretion [25] and targeting of LLC to the extra-
cellular matrix where transglutaminases covalently link the LTBP to
ECM proteins such as ﬁbronectin [26–28]. Therefore TGFβ is regulated
both temporally and spatially, due to the requirement for activation
and sequestration in the ECM.
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TGFβ. Activation has been reported to occur by a number of mecha-
nisms: Cell surface integrins bind LAP via the RGDmotif allowing prote-
ase enzymes to release active TGFβ [29]. Integrin interaction with LAP
can also result in the release of active TGFβ through tensional forces be-
tween the cell and ECM [30]. The Mannose-6-phosphate/Insulin like
growth factor type II receptor (M6P/IGF-II) can bind to LAP which
causes cell surface localisation of the latent complex and results in acti-
vation of TGFβ through proteolytic cleavage [31,32]. Thrombospondin
can interact with LAP via an LSKL motif resulting in a conformational
change in the latent complex and TGFβ activation (exclusive of release
from the complex) [33]. TGFβ is regulated on many levels, through in-
tracellular post-translational modiﬁcation, localisation to the ECM and
through a variety of activation mechanisms.
In the canonical signalling pathway, active TGFβ binds cell surface
TGFβ type I and type II receptors (TGFβRI and TGFβRII)—these recep-
tors have serine/threonine kinase activity. Upon ligand binding, both
type I and type II receptors form heterotetrameric complexes, TGFβRII
phosphorylates TGFβRI, leading to phosphorylation and subsequent
activation of SMAD proteins which translocate to the nucleus and
cause transcriptional regulation of target genes (for review see;
[20]). Since TGFβ is known to play a major role in wound healing
and ﬁbrosis, knowledge of its role and regulation in tendon is likely
to be important in understanding the cause and progression of
tendinopathy.
Tendinopathies are thought to be preceded by changes in cellular
activity resulting in modiﬁed ECM composition, which weaken the
tendon [16]; however these changes are not fully understood. Metal-
loproteinases are proteases which largely control the homeostasis of
the ECM [34,35]. mRNA expression analysis has shown that a number
of these molecules are regulated in tendinopathies [36–40]. Metallo-
proteinases are subdivided into a number of protein families; matrix
metalloproteinases (MMPs), A Disintegrin and Metalloproteinase do-
main (ADAM) and A Disintegrin and Metalloproteinase domain with
Thrombospondin repeats (ADAM-TS). MMPs, ADAMs and ADAM-TSs
are important in the process of extracellular matrix degradation.
Generally, members of the MMP family (MMP-1, -2, -8, -13 -14) medi-
ate ﬁbrillar (types I, II and III) collagen degradation, members of the
ADAM-TS family (ADAMTS-1, -4, -5, -9, -15) degrade ECM proteogly-
cans such as aggrecan and versican and ADAMs are involved in process-
ing of membrane proteins through shedding of the ectodomain [41].
Tissue inhibitors of metalloproteinases (TIMPs), of which there are
four members, inhibit MMP and ADAM activity, thereby inhibiting the
degradation of the ECM (formetalloproteinase reviews see: [34,42,43]).
Mechanical strain has been implicated in the development of
tendinopathy, either initiating matrix damage directly or by modify-
ing the cellular activity, although certain levels of strain are vital for
the homeostasis of tendon [44–46]. Mechanical strain has been re-
ported to modulate the expression and activity of a number of metal-
loproteinases [47–51], although to date no studies have investigated
mechanical regulation of the entire metalloproteinase family. We
have previously shown that almost all MMP and ADAMTS enzymes
are expressed in normal tendon, with different patterns of expression
in normal, painful and ruptured tendon [36]. Although the pattern of
metalloproteinase expression was similar in Achilles and posterior
tibialis tendinopathy [36,52], there are differences in the expression
of some genes that we speculate may be related to differences in me-
chanical loading [53].
The primary aim of this study was to investigate the response of
the majority of metalloproteinases and selected matrix genes to 5%
cyclic mechanical strain due to the lack of existing studies on the me-
chanical regulation of such a wide range of genes. We hypothesised
that 5% strain would give rise to anabolic changes in MMP and matrix
genes. Our observations conﬁrmed that this was the case. Secondly,
since TGFβ protein expression is stimulated in tendinopathy [18,19]
and pathway analysis following global gene expression proﬁling ofchronic tendinopathic tendon tissue also showed an increase in genes
related to TGFβ signalling, we were interested in the regulation of
tenocyte gene expression by TGFβ. We hypothesised that strain and
TGFβ would have similar affects upon metalloproteinase and matrix
gene expression, due to the anabolic responses reported in both strain
(in the current study) and TGFβ (in previous studies: [54–63]). The
analogous response of the majority of genes to strain and TGFβ sug-
gested that TGFβ signalling may be involved in strain regulation of
gene expression. To test this hypothesis an inhibitor of TGFβRI which
inhibits downstream phosphorylation of SMAD [64] was added to
tenocyte cultures. We demonstrated that inhibition of TGFβRI abrogat-
ed the strain mediated response. In order to test whether TGFβ protein
levels were modiﬁed in response to mechanical loading, we measured
total and active TGFβ in strain conditioned medium using a cell based
luciferase assay [65]. We hypothesised that TGFβ would be regulated
at the protein level with mechanical loading. Our observations showed
that TGFβ activation, rather than gene expression, plays an important
role in mechanotransduction.
2. Materials and methods
2.1. Cell culture
Human Achilles tenocytes derived from tendinopathic tissue by ex-
plant outgrowth (bpassage 10) were grown to ~90% conﬂuence in
Dulbecco's modiﬁed Eagle's medium (DMEM) (low glucose, glutaMAX
and pyruvate [Life Technologies, Paisley, UK]) containing heat
inactivated foetal bovine serum and penicillin (10 mg/ml)/streptomy-
cin (10 U/ml) (Life Technologies, Paisley, UK) at a ratio of 100:10:1.
Tenocyte seeded 3D collagen gels were prepared essentially as de-
scribed by Albert Banes and colleagues [66]. In brief, rat tail collagen
(2.2 mg/ml, First Link, Birmingham, UK) was mixed with 10× DMEM
(Life Technologies, Paisley, UK) at a ratio of 9:1 and the pHwas adjusted
to approximately 7 by the addition of 10 M NaOH. Neutralised collagen
and tenocyte suspension were mixed 1:1 (1 mg/ml collagen,
1.5 × 106 cells/ml ﬁnal density) and 200 μl was pippetted into ﬂexible
bottomed collagen I coated ﬂexcell tissue train plates, under 20% vacu-
um. The cell density was selected based on pilot experiments, which
showed similar changes at low and high cell densities, but the response
was greater at high cell density. Gelswere allowed to polymerise for 1 h
at 37 °C, at which point 3 ml serum free DMEMwas added. After a fur-
ther 72 h medium was replaced, appropriate treatments added [TGFβ
1–5 ng/ml (R&D systems, Abington, UK), TGFβ receptor I inhibitor
(SB431542) 10 μM, MMP inhibitor (GM6001) (Millipore, Watford,
UK) 10 μM, serine protease inhibitor (Pefabloc) 0.5 mM, RGD peptide
inhibitor and control peptide (GRGDSP and GRGESP) (Cambridge Bio-
science, Cambridge, UK) [67] 7 μM, thrombospondin peptide inhibitor
and control peptide (LSKL and SLLK) (Cambridge Bioscience, Cam-
bridge, UK) [68,69] 13 mM, Mannose-6-phosphate (M6P) 10 μM and
appropriate vector controls (sourced from Sigma Aldrich, Dorset, UK,
unless otherwise stated)] and a uniaxal strain applied using the Flexcell
FX-4000™ tissue train unit (Dunn Labortechnik, Asbach, Germany);
uniaxial strain was applied in sinusoidal wave form at 5% cyclic strain
at 1 Hz for up to 48 h.
2.2. RNA extraction and reverse transcription
Tenocyte seeded collagen gels were dissolved in 4× the gel vol-
ume of Trizol reagent (Life Technologies, Paisley, UK). RNAwas isolat-
ed as described previously using a tri-spin protocol [70] and
re-suspended in 50 μl of analytical grade water. The RNA concentra-
tion of samples was estimated using a nanodrop spectrophotometer.
The absorbance ratio A260:A280 was 1.76 ± 0.005 (mean ± S.E.M.)
with an average concentration of 43 ng/μl ± 0.5 (mean ± S.E.M.).
RNA was diluted to 23–40 ng/μl depending on the experimental set.
RNA was primed using random hexamers and reverse transcribed
Table 1
Quantitative Real Time PCR primer probe sets.
Gene Sequences Reference
MMP1 Forward primer: 5′-AAGATGAAAGGTGGACCAACAATT-3′
Reverse primer: 5′-CCAAGAGAATGGCCGAGTTC-3′
Probe: 5′-FAM-CAGAGAGTACAACTTACATCGTGTTGCGGCTC-TAMRA-3′
[101]
MMP3 Forward primer: 5′-TTCCGCCTGTCTCAAGATGATAT-3′
Reverse primer: 5′-AAAGGACAAAGCAGGATCACAGTT-3′
Probe: 5′-FAM-TCAGTCCCTCTATGGACCTCCCCCTGAC-TAMRA-3′
[102]
MMP13 Forward primer: 5′-AAATTATGGAGGAGATGCCCATT-3′
Reverse primer: 5′-TCCTTGGAGTGGTCAAGACCTAA-3′
Probe: 5′-FAM-CTACAACTTGTTTCTTGTTGCTGCGCATGA-TAMRA-3′
[102]
ADAM12 Forward primer: 5′-AGCTATGTCTTAGAACCAATGAAAAGTG-3′
Reverse primer: 5′-CCCCGGACGCTTTTCAG-3′
Probe: 5′-FAM-ACCAACAGATACAAACTCTTCCCAGCGAAGA-TAMRA-3′
[36]
COL1A1 Forward primer: 5′-CTGGTCACCATGGTGATCAAG-3′
Reverse primer: 5′-GCAGGCGGGAGGACTTG-3′
Probe: 5′-CTGTCGATGGCTGCACGAGTCACAC-TAMRA-3′
[70]
ADAMTS5 Forward primer: 5′-TGTCCTGCCAGCGGATGT-3′
Reverse primer: 5′-ACGGAATTACTGTACGGCCTACA-3′
Probe: 5′-FAM-TTCTCCAAAGGTGACCGATGGCACTG-TAMRA-3′
[103]
TGFβ1 Forward primer: 5′-TGAGGGCTTTCGCCTTAGC-3′
Reverse primer: 5′-CGGTAGTGAACCCGTTGATGT-3′
Probe: 5′-FAM-CTCCTGTGACAGCAGGGATAACACACTGC-TAMRA-3′
Own design
TGFβ2 Forward primer: 5′-ACGGATTGAGCTATATCAGATTCTCA-3′
Reverse primer: 5′-AACAGCATCAGTTACATCGAAGGA-3′
Probe: 5′-FAM-TTTAACATCTCCAACCCAGCGCTACATCG-TAMRA-3′
Own design
TGFβ3 Forward primer: 5′-TGTCACACCTTTCAGCCCAAT-3′
Reverse primer: 5′-CTCCACGGCCATGGTCAT-3′
Probe: 5′-FAM-ATTGTCCACGCCTTTGAATTTGATTTCCAT-TAMRA-3′
Own design
TOP1 Primer design kit Primer design kit
18s Forward primer: 5′-GCCGCTAGAGGTGAAATTCTTG-3′
Reverse primer: 5′-CATTCTTGGCAAATGCTTTCG-3′
Probe: 5′-ACCGGCGCAAGACGGACCAG-3′
[13]
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to manufacturer's instruction.
2.3. Taqman Low Density Array (TLDA) analysis
The TLDA (Life Technologies, Paisley, UK) was designed to assess
all 23 MMP genes as well as 18 of the 19 ADAMTS genes, all 4 TIMP
genes, 10 key proteoglycan and 4 collagen genes, as well as the en-
dogenous control gene 18s. 50 ng (MMP, ADAMTS and TIMP) or
243 ng (proteoglycan and collagens) cDNA was loaded into the ﬁll
reservoirs and the plate was run according to manufacturer's instruc-
tions (Using the Applied Biosystems 7900HT Real-Time PCR System
and Applied Biosystems Sequence Detection Systems (SDS) software
[Life Technologies, Paisley, UK]). Undetected samples were given a
Ct value of 40. Relative expression levels in each gene of interest
were analysed by normalising to endogenous control gene 18s (ΔCt
[endogenous control gene Ct–gene of interest Ct]) and expressing
the data as 2ΔΔCt. All data were normalised to the control, which is
represented by the baseline value of 1.
2.4. Quantitative Real Time PCR
The standard qRT-PCR programme was run using selected
primer probe sets (see Table 1) and the Applied Biosystems 7500
Taqman system. Each reaction was performed in a volume of
25 μl including; 11–19 ng/well of cDNA (depending on the exper-
imental set), 50% KAPA Probe fast qPCR kit Mastermix (2×)
(Anachem, Bedfordshire, UK), 10 nM each of the forward and re-
verse primer and 5 nM of probe. Standard curves were run for
each assay to conﬁrm primer probe efﬁciency. Relative expression
levels in each gene of interest were analysed by normalising to en-
dogenous control genes Topoisomerase-1 (TOP1) and 18s (ΔCt
[endogenous control gene Ct–gene of interest Ct]) and expressing
the data as 2ΔΔCt. All data were normalised to the control, which
is represented by the baseline value of 1. Data shown wasnormalised to TOP1, as GeNorme analysis demonstrated TOP1 to
be the most stable housekeeping gene (normalising to 18s yields
similar results).
2.5. TGFβ luciferase assay
In order to test whether TGFβ protein levels were modiﬁed in re-
sponse to mechanical loading, we measured total and active TGFβ in
strain conditioned medium using a cell-based luciferase assay [65].
SW1353 chondrosarcoma cells were transfected with CAGA and
Renilla [65] constructs simultaneously (Renilla is used to control for
transfection efﬁciency) using Fugene 6 (Sigma Aldrich, Dorset, UK).
Cells were serum-starved for 24 h before 6 h incubation with condi-
tioned medium from 48 h strained/non-strained cultures. Duplicate
samples of conditioned mediumwere heated for 5 min at 80 °C to ac-
tivate TGFβ before incubation with SW1353 cells. The Promega Dual
luciferase™ reporter assay kit (Southampton, UK) was used to mea-
sure luciferase activity according to manufacturer's instructions. The
absorbance was measured using a PerkinElmer spectrophotometer
(Cambridge, UK) at 560 nm. CAGA luciferase units were normalised
to Renilla luciferase units to account for transfection efﬁciency
(CAGA Luciferase units/Renilla luciferase units). These values were
normalised to the non-conditioned medium controls and expressed
as a percentage of the total TGFβ in non-strained controls. Speciﬁcity
of this assay for TGFβ was determined by the addition of a pan inhib-
itory antibody against TGFβ or a TGFβRI inhibitor in combination
with conditioned medium from multiple strain experiments.
2.6. Statistical analysis
Data were presented as a mean ± Standard error (S.E.M.). Data
were tested for normal distribution using the Shapiro–Wilk normality
test. The Wilcoxon signed rank test and the students paired T test (2
tailed, assuming unequal variance) were used to analyse qRT-PCR
Fig. 1. Taqman Low Density Array of strain modulated metalloproteinase and matrix genes; ADAMTS (A), TIMP (A), MMP (B) and matrix proteins (C). Quantitative Real Time PCR
(Taqman Low Density Array Data) analysis of cells seeded at 1.5 × 106 cells/ml in type I rat tail collagen at 1 mg/ml following 5% cyclic strain for 24 and 48 h. The dotted line rep-
resents the two fold modulation point. Data were normalised to 18s and expressed as a ratio of strain: non-strain (n = 3). Signiﬁcant values are indicated as * (p b 0.05).
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Table 2
Comparison of changes in gene expression with strain and TGFβ. Fold changes with
strain and TGFβ were calculated compared to controls (non-strained and non-treated
with TGFβ). Increases in gene expression are represented by +, decreases in gene ex-
pression are represented by −.
24 h 48 h
TGFβ Strain TGFβ Strain
ADAMTS1 − − − −
ADAMTS2 − − − −
ADAMTS3 − − − −
ADAMTS4 + + + +
ADAMTS5 − + − −
ADAMTS6 + + + +
ADAMTS7 − − − −
ADAMTS9 − − − −
ADAMTS10 − − − +
ADAMTS12 − − − −
ADAMTS13 − − − −
ADAMTS14 + + − +
ADAMTS16 + + + +
ADAMTS17 − − − −
MMP1 − − − −
MMP2 − − − −
MMP3 + − − −
MMP7 + + − −
MMP8 − − − −
MMP9 − − − −
MMP10 + + − −
MMP11 − − − −
MMP13 − − − −
MMP14 − − − −
MMP15 + −
MMP16 − − − +
MMP17 − − − −
MMP19 − − − −
MMP23 + − − −
MMP24 + + + +
MMP27 − − + +
TIMP1 − − − −
TIMP2 − − − −
TIMP3 + + − −
TIMP4 − − − −
Aggrecan − − + +
Biglycan − − − −
Decorin − − − −
Lumican − − − −
Versican − − − −
Fibronectin − − − −
COMP − − + +
Fibrillin + + + +
Link protein − − − −
Thrombospondin + + − +
COL1A1 + + + +
COL3A1 − − − −
COL12A1 − − − −
COL14A1 − − − −
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chosen as the cut off for statistical signiﬁcance.
3. Results
3.1. Screen of mRNA expression with mechanical strain
In order to identify strain responsive genes we measured the ex-
pression of all 23 MMP, 4 TIMP and 18 ADAMTS mRNA and a selection
of matrix genes using a Taqman Low Density Array (Fig. 1). Of these
genes we were unable to detect ADAMTS8, ADAMTS15, ADAMTS18,
ADAMTS19, MMP12, MMP20, MMP21, MMP25, MMP26, MMP28
and COL2A1.
There was a signiﬁcant increase in the following genes with strain
compared to non-strained controls at 24 and 48 h; ADAMTS2 (2.5 and
2 fold), ADAMTS4 (3.2 and 7.1 fold), ADAMTS16 (25.6 and 24.1 fold),
MMP24 (5.2 and 35.2 fold) and TIMP3 (4.6 and 5.3 fold) (at 24 and
48 h respectively). MMP10 was increased with strain after 24 h (53.5
fold) and decreased after 48 h (4 fold). Thrombospondin-1 (8.6 fold),
ADAMTS6 (3.6 fold) and ADAMTSS14 (3 fold) were increased and
MMP11 was decreased (1.6 fold) after 24 h of strain. Lumican (1.4
fold), MMP3 (33.3 fold) and MMP17 (2 fold) were decreased and
ADAMTS10 (2.6 fold) is increased after 48 h of strain.
Using histological analysis we observed that cells became aligned
to the axis of load and that there was no difference between strained
and non-strained cultures (data not shown), similar to previous re-
ported observations [66].
3.2. Screen of mRNA expression with TGFβ
Using a real time PCR array, we conﬁrmed that the majority of
gene changes were similar with strain or TGFβ treatment; 12/14
ADAMTSs, 14/17 MMPs and 13/14 of matrix genes showed a similar
response to strain and TGFβ at 24 and 48 h. Three out of the four
TIMPs also showed similar responses to strain and TGFβ (see
Table 2, for a comparison of changes with TGFβ and strain). Genes
that showed dissimilar responses included; ADAMTS5, ADAMTS7,
MMP7 and MMP16 which were decreased with TGFβ and increased
with strain at 24, 24, 48 and 48 h respectively. MMP15 and TIMP4
were increased with TGFβ and decreased with strain at 48 h.
3.3. Selected gene regulation with strain or TGFβ
We selected metalloproteinase and matrix genes that responded
to mechanical strain in the array for further time course analysis.
MMP1, MMP2 and MMP13 were selected on the basis of their regula-
tion with strain in the TLDA and key role in tendon matrix turnover.
ADAM12 was chosen as we had previously shown its regulation in
tendinopathy [36]. COL1A1 was selected as it is the main collagen
expressed in tendon and it was regulated with strain in our TLDA
screen. ADAMTS5 was chosen as it responded differently to mechan-
ical load and TGFβ, unlike many of the other genes, and it has also
been shown to be regulated in tendinopathy. MMP1 (3.3 fold, 15.3
fold) and MMP13 (2.3 fold, 5.7 fold) were signiﬁcantly decreased
with 5% cyclic strain or TGFβ at 48 h (Fig. 2). MMP13 was also signif-
icantly decreased (1.7 fold, 3 fold) at 24 h with both strain and TGFβ
(error bars are variable due to low expression of MMP13). ADAM12
(2.1 fold, 2.4 fold), and COL1A1 (1.8 fold, 2.2 fold) were signiﬁcantly
increased with 24 h of cyclic strain or TGFβ. ADAMTS5 (2.2 fold)
and MMP3 (2.3 fold) were signiﬁcantly increased at 24 h and
MMP3 (1.38 fold) was signiﬁcantly decreased at 48 h in response to
strain. Although ADAMTS5 and MMP3 showed a similar pattern of
regulation with TGFβ, this was not signiﬁcant. The majority of TGFβ
mRNA responses in our system show changes analogous to those
seen with mechanical strain. Strain responses in the presence of
TGFβ show that there is little effect of strain over and above TGFβstimulation in most cases and in general the responses with TGFβ
were more robust than those with strain. However ADAMTS5 was
the exception, as TGFβ did not regulate ADAMTS5 signiﬁcantly.
3.4. Inhibition of TGFβRI abrogates the mRNA response to strain
The addition of a TGFβRI inhibitor abrogated the TGFβ mediated
response; In MMP1, MMP3, ADAM12 and COL1A1 mRNA expression
there was a signiﬁcant difference between TGFβ treated cultures ±
TGFβRI inhibitor at 48 h (p b 0.05) (Fig. 3). Addition of the TGFβRI in-
hibitor also abrogated responses to strain in MMP1, MMP3, ADAM12
and COL1A1 at 48 h. This suggests that strain signals via TGFβRI in the
TGFβ signalling pathway. Even in the non-strained control cultures
the addition of TGFβRI inhibitor caused mRNA levels to change in
the opposite direction to the strain response, indicating a basal level
of TGFβ signalling in non-strained cultures. This may be due to the
tensional forces present across the tenocyte seeded collagen gel in
Fig. 2. Strain and TGFβ modulation of metalloproteinases and matrix genes. Quantitative Real Time PCR analysis of cells seeded at 1.5 × 106 cells/ml in type I rat tail collagen at
1 mg/ml after 5% cyclic strain over a time course of 0–48 h. Data were normalised to TOP1 and expressed as a ratio of strain: non-strain, TGFβ: control or strain plus TGFβ: control
(n N 6). Signiﬁcant values are indicated as * (changes with strain) or # (changes with TGFβ) (p b 0.05).
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as their regulation appears to be independent of TGFβRI signalling.
3.5. Strain regulation of TGFβ protein and mRNA
Following our observation that TGFβ signalling plays a role in the
response to cyclical strain, we measured TGFβ1, TGFβ2 and TGFβ3
mRNA expression. TGFβ1 and TGFβ3 mRNA were signiﬁcantly de-
creased with strain at 8 h (~1–2 fold) (Fig. 4A) and TGFβ2 and
TGFβ3 mRNA were signiﬁcantly decreased at 24 h with strain (~2
and 3 fold respectively). Therefore there was no signiﬁcant increase
in the level of TGFβmRNA expressed in response to strain. Therefore,
regulation of TGFβ at the mRNA level could not explain the increase
in TGFβ signalling stimulated with mechanical strain.
Strain conditioned medium induced a signiﬁcantly higher level of
SMAD activity compared to conditioned medium from non-strained
controls (~40 fold increase) (Fig. 4B). Heat-activated conditioned me-
dium, measuring total TGFβ, did not show a signiﬁcant difference in
SMAD activity between strained and unstrained cultures. The speci-
ﬁcity of this assay was conﬁrmed by the addition of TGFβRI inhibitor
and a Pan-TGFβ antibody (inhibits all TGFβ isoforms) to conditioned
media and recombinant TGFβ (see Fig. 4C and D). The addition ofthese inhibitors to strain conditioned media completely abrogated
the detection of TGFβ, conﬁrming that the assay is speciﬁcally
detecting TGFβ. This indicated that activation and not total TGFβ
was increased in response to mechanical loading and that TGFβ acti-
vation was a key step in the mechanotransduction and regulation of
metalloproteinase and matrix genes.
3.6. Investigation of TGFβ activation mechanisms
MMPs (MMP2, MMP9 and MMP14) and serine proteases (throm-
bin and plasmin) have been reported to activate TGFβ by cleaving
TGFβ from LAP [29,71]. In order to test the involvement of proteases
in the activation of TGFβ in response to mechanical strain, a broad
spectrum MMP inhibitor (GM6001) and a serine protease inhibitor
(pefabloc) were added to tenocyte seeded 3D collagen gels before
straining. After 48 h SMAD activity was measured using the luciferase
assay. SMAD activity was not signiﬁcantly different from controls (see
Fig. 5). This indicates that the SMAD activatory soluble factor is not
activated via protease cleavage; at least those inhibited by GM6001
or pefabloc, in response to mechanical strain.
TGFβ does not require physical separation from the LAP for activa-
tion; interaction of LAP with integrin and thrombospondin domains
Fig. 3. TGFβRI inhibition of strain mediated responses. Quantitative Real Time PCR analysis of cells seeded at 1.5 × 106 cells/ml in type I rat tail collagen at 1 mg/ml (±TGFβRI in-
hibitor, 10 μM) after 5% cyclic strain at 48 h. Data were normalised to TOP1 and expressed as a ratio of strain: control or TGFβ: control (n N 6). All data were normalised to the
control without TGFβRI inhibitor, which is represented by the baseline value 1 in each graph. Signiﬁcant values are indicated as @ (control compared to control plus inhibitor),
* (strain compared to strain plus inhibitor) and # (TGFβ compared to TGFβ plus inhibitor) (p b 0.05).
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change and consequent activation of TGFβ [30,33,67,72]. RGD and
LSKL mimetic peptides were added to tenocyte seeded 3D collagen
gels before straining to inhibit this interaction. After 48 h strain
SMAD activity was measured using the luciferase assay. SMAD activ-
ity was not signiﬁcantly different from controls (see Fig. 5). This indi-
cates that integrin and thrombospondin interaction with latent
soluble factor is not involved in strain mediated activation of the
SMAD activatory soluble factor.
The M6P/IGF-II receptor has also been reported to be involved in
the activation of TGFβ [31,32]. LAP can bind to M6P/IGF-II which
causes cell surface localisation of the latent complex and may result
in activation of TGFβ through proteolytic cleavage [32]. Addition of
Mannose-6-phosphate (M6P) prevents this interaction and therefore
inhibits TGFβ activation [32]. M6P was added to tenocyte seeded 3D
collagen gels before straining to test whether M6P is involved in
strain mediated TGFβ activation. After 48 h strain SMAD activity
was measured using the luciferase assay. SMAD activity was not sig-
niﬁcantly different from controls (see Fig. 5). Therefore none of the
well characterised mechanisms of TGFβ activation tested in thisstudy was demonstrably responsible for the strain mediated activa-
tion of the SMAD activatory soluble factor. This indicates that a poten-
tially novel mechanism of activation is stimulated in response to
mechanical strain in tenocytes.
4. Discussion
We are the ﬁrst to study the effect of mechanical regulation on an
array of protease genes in human tenocytes. We have chosen a strain
of 5% as it is within the physiological range experienced by human
tendons [73,74]; given that some tendons can elongate 12–15% [74],
values for cell strain of 4–5% may be considered within the physiolog-
ical range, at least for highly loaded tendons such as the Achilles. Our
data shows that 5% mechanical strain has a potential anabolic effect
on the collagenous matrix, as the two main collagenases (MMP1
and MMP13) are decreased with mechanical strain, accompanied by
an increase in COL1A1 expression.
There have been a number of studies that have looked at the ef-
fects of mechanical strain on MMPs, mainly in rodent tendon in
vivo, ex vivo or in vitro cell studies. Obvious limitations of these
Fig. 4. TGFβ activation is increased with mechanical strain. (A) Quantitative Real Time PCR analysis of TGFβ isoforms in cells seeded at 1.5 × 106 cells/ml in type I rat tail collagen at
1 mg/ml after 5% cyclic strain over a time course of 0–48 h. Data were normalised to TOP1 and expressed as a ratio of strain: non-strain (n N 6). Signiﬁcant values are indicated as
* (TGFβ1), @ (TGFβ2) or # (TGFβ3). (B) A cell based luciferase assay measuring levels of SMAD activatory soluble factor (see Methods for details). Data were normalised to trans-
fection controls and negative controls (n = 5). Signiﬁcant values are indicated as * (p b 0.05). In order to conﬁrm that TGFβ signalling and more speciﬁcally TGFβ activity are
responsible for the stimulation of SMAD activity, inhibitors of TGFβ activity and TGFβ signalling were used. Non-conditioned media ± TGFβ, strain and non-strain conditioned
media were incubated with TGFβRI inhibitor (C) and a Pan speciﬁc TGFβ inhibitory antibody (D) to conﬁrm that the measure of SMAD activation was stimulated via TGFβ.
Signiﬁcant values are indicated as * (p b 0.05) (n = 3).
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MMP1; instead they only express MMP13, which is the nearest ho-
mologue [47,75]. In some studies 2D models lack the cell–matrix
contact that is so obviously important in the 3D matrix seen in
vivo [76–78]. Although it is difﬁcult to compare studies of different
design, studies focusing on strains of lower magnitude are reported
to have an anabolic effect upon the tendon, consistent with thecurrent study [47,48,51,75,79,80]. However, a number of rodent
tendon in vivo and in vitro studies have shown no signiﬁcant
change in MMP3 or MMP13 mRNA upon moderate loading
[50,51,77,79], this may be due to a lower frequency in strain
(b0.5 Hz) or the reduced loading time. This is consistent with our
data as MMP1, MMP3 and MMP13 are not signiﬁcantly regulated
by strain until 48 h.
Fig. 5. Inhibition of potential TGFβ activation mechanisms. Conditioned media was collected from cells seeded at 1.5 × 106 cells/ml in type I rat tail collagen at 1 mg/ml and cycli-
cally strained at 5% for 48 h with the addition of MMP inhibitor, GM6001 (10 μM); serine protease inhibitor, Pefabloc (0.5 mM); RGD peptide inhibitor, GRGDSP (7 μM);
thrombospondin peptide inhibitor, LSKL (13 mM) and Mannose-6-phosphate, M6P (10 μM). A cell based luciferase assay measuring levels of SMAD activatory soluble factor
was used to assess TGFβ (see Methods for details). Data were normalised to transfection controls and negative controls before expression as a percentage of total SMAD activatory
soluble factor in non-strain samples (n = 3, except the M6P data where n = 1 is shown, this data is representative of 2 other repeats).
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lation of MMP10, MMP24, the ADAMs, TIMPs 3 and 4 and such a large
array of ADAMTS and matrix proteins at either the mRNA or protein
level in human tendon. Our data suggests that generally there is a de-
crease in MMPs (MMP1, -3, -11, -13 and -17) and an increase in col-
lagen at the mRNA level. We have also shown an increase in TIMP3
mRNA which is known to inhibit ADAM12, MMP1, MMP2, MMP3,
ADAMTS4 and ADAMTS5 at the protein level [81–83]. Although to
conﬁrm this TIMP3 protein quantiﬁcation and activity measurement
are required. This supports earlier reports that moderate cyclic strain
is largely anabolic, i.e. maintaining the collagen components of the
ECM.
Vogel showed stimulation of aggrecan with TGFβ, which is possi-
bly similar to the current study [84]. The is no evidence to suggest
that the tenocytes are differentiating to the chondrogenic phenotype,
as chondrogenic markers such as SOX9 and collagen type II are not el-
evated with mechanical strain and tendon related genes such as
tenascin C, thrombospondin 4 and scleraxis are signiﬁcantly in-
creased with strain. Proteoglycan regulation has also been reported
in a rat tail tendon model. After a cyclic loading regime of 3% overlay-
ing a 2% static strain for 24 h decorin, ﬁbronectin and biglycan mRNA
was decreased, increased and unchanged respectively [79,85]. The
current study showed no signiﬁcant changes in any of the above pro-
teoglycans. No other published studies have looked into any other
proteoglycans at the RNA level in response to mechanical load.
Arnoczky's group has shown that mechanical strain is important
in tendon ECM homeostasis in that MMPs are increased with the ab-
sence of tension [45,47,48,75]. Data from Smith et al. also support this
[86]. In addition, Arnoczky's group has proposed that stress depriva-
tion, caused by isolated tendon ﬁbre damage due to a single abnormal
over load, is a key factor in tendinopathy, as opposed to catabolic ef-
fects induced by a cellular response to high levels of repetitive strain
[87]. Although fatigue loading has been shown to disrupt collagen ﬁ-
bres [88], load induced tendon catabolism requires a level of strain
that does not “normally” occur in the tendon in vivo [87]. In the cur-
rent study we have shown little evidence of load inducing catabolic
effects, hence our data support Arnoczky's ideas. Therefore it is im-
portant for us to fully elucidate the process of mechanotransduction
to truly understand the underlying factors contributing to the devel-
opment of tendinopathy.Comparing the responses of metalloproteinase and matrix genes
to strain and tendinopathy may shed light on the relationship be-
tween mechanical loading and tendinopathy development. MMP2,
MMP3, MMP8, ADAMTS2, ADAMTS4, ADAM12 and collagen type I ex-
pression were regulated in a similar manner in tendinopathy com-
pared to the current study [15,36,38,57,70,89,90]. However, MMP1,
MMP13, MMP10, ADAMTS5, TIMP3, versican, aggrecan, biglycan,
decorin, ﬁbronectin, ﬁbrillin and COMP showed an opposite response
with strain compared to tendinopathy [10,13,15,36–38,40,89,90]. The
similarity between strain responses and changes in tendinopathy in
terms of gene expression suggests that an altered strain regime may
contribute to the development of tendinopathy. However, variation
in response to strain and tendinopathic changes suggests that
tendinopathies are complex and there may be other causative factors
other than mechanical loading.
TGFβ protein is increased in tendinopathy [18,19]. Pathway analysis
following global gene expression proﬁling of chronic tendinopathic ten-
don tissue also showed an increase in genes related to TGFβ signalling
[89]. We have compared gene regulation in tendinopathy and response
to mechanical load. We showed that there were many similarities.
However gene expression also suggests that the mechanotransduction
mechanism has been disrupted in some way in tendinopathy, as there
were also some differences in the response to mechanical load and
those seen in tendinopathy. This indicates that TGFβ signalling response
to load may be disrupted in some way. Abnormal loading regimes may
result in differential response of TGFβ and contribute to the develop-
ment of tendinopathy.
We have shown that the vast majority of changes reported in re-
sponse to strain have shown a similar pattern of response to TGFβ.
Some of the gene changes in response to TGFβ have previously been
reported in other cell types. For example TGFβ is reported to regulate
ADAM12 [54], ADAMTS1 [55], ADAMTS4 [56,57], ADAMTS16 [58],
TIMP3 [59], TIMP4 [60], thrombospondin [61], aggrecan [62], collagen
and ﬁbronectin [63]. These responses are analogous to those seen in
our model with TGFβ and strain, further supporting our conclusion
that TGFβ plays a key role in the strain regulation of most metallopro-
teinase genes. ADAMT5 has been shown to either be unresponsive
[56] or to decrease [55] in response to TGFβ. This corresponds with
the current study in that induction of ADAMTS5 by strain is not relat-
ed to TGFβ signalling directly. Recent research has also reported that
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radation of aggrecan, allowing TGFβ to access receptor molecules
[91]. The increase of ADAMTS5 in our system in response to strain
may increase TGFβ signalling. Despite the fact that MMP13 shows
similar response to strain and TGFβ, regulation does not appear to
be mediated via the TGFβRI pathway either. This indicates that regu-
lation of MMP13 by TGFβ is via a non-canonical TGFβ signalling
pathway.
In some instances there is an additive effect when both strain and
TGFβ are applied. ADAMTS5 is increased signiﬁcantly with strain after
24 h (2.2 fold), in response to TGFβ there was a trend to increase,
however with a combination of strain and TGFβ treatment ADAMTS5
was increased further than strain alone (2.8 fold, 24 h). ADAMTS5
stimulation with strain is not mediated via TGFβRI signalling there-
fore strain and TGFβ response rely on different mechanisms. We
have also noted that the increase in elastin was reduced when strain
and TGFβ were combined; elastin was increased 3.8 fold with strain,
27.5 fold with TGFβ and 11.2 fold with strain and TGFβ in combina-
tion. We have shown that elastin was regulated via TGFβRI however
we have not fully characterised this response. In speculation, this
may result from a negative feedback mechanism triggered when the
levels of TGFβ reach a threshold; however more research is required
to test this hypothesis.
Limitations of the study include the sole use of tendon cells de-
rived from tendinopathic tissue. However, we have studied a num-
ber of cell isolates derived from normal and ruptured tendon,
which showed similar responses in terms of metalloproteinase reg-
ulation with strain (data not shown). This suggests that tendon
cells derived from different disease phenotypes respond in a simi-
lar way to cells derived from normal tendon when cultured. In ad-
dition, as we seed the tenocytes into a simple collagen matrix
which is lacking in many of the components of the ECM that occur
in vivo, tenocytes may respond differently to mechanical loading
than those in native ECM. Further study of TGFβ involvement in
gene regulation with mechanical strain in tendon fascicles would
conﬁrm whether tenocytes respond in a similar manner in their na-
tive environment. Another limitation of this study is that we were
unable to conﬁrm that all inhibitors used to characterise mecha-
nisms of TGFβ activation were effective although we were able to
conﬁrm the inhibitory ability of GM6001 after 48 h of culture,
which was achieved using a quenched ﬂuorescent substrate and
active metalloproteinase (data not shown). Other inhibitors were
used at concentrations more than or equal to those reported in
similar studies (M6P and pefabloc [92]; LSKL [68,69]; RGD peptide
[67]).
Taken together our data suggest that activation of TGFβ and
subsequent TGFβ signalling is part of the mechanotransduction re-
sponse of tenocytes to moderately high levels of strain. TGFβ
up-regulation at both the protein and mRNA level with mechanical
strain has been previously reported in tenocytes [93,94] and other
cell types [95–98]. TGFβ has also been implicated as a regulatory
step in the mechanical regulation of collagen [94,99], although
these studies have not speciﬁcally shown that activation of TGFβ
is involved. Maeda et al. [100] have reported TGFβ activation as a key
regulator of scleraxis expression (a transcription factor expressed in the
developing tendon rudiment); although they did not how total levels of
TGFβ. We are the ﬁrst to implicate TGFβ activation (and not protein or
mRNA synthesis) as a key regulator in the mechanoregulation of
metalloproteinases and other matrix genes. As ADAMTS5 is not
regulated via the same TGFβ signalling pathway, this suggests
that there is an alternative mechanotransduction pathway. This
pathway may involve crosstalk with or may precede TGFβ activa-
tion. The next goal is to elucidate the mechanism by which me-
chanical strain induces latent TGFβ activation, since doing so could
help us to fully understand how we could treat and ultimately prevent
tendon disease.5. Conclusions
We have shown that mechanical strain regulates multiple prote-
ase and matrix genes at the mRNA level and that changes in mRNA
level are analogous to those induced by TGFβ stimulation. Further-
more, the inhibition of the TGFβ signalling pathway abrogated the
strain-induced changes in mRNA level, demonstrating signalling via
TGFβRI which mediates downstream phosphorylation of SMAD [64].
This indicates that signalling is mediated via the canonical TGFβ sig-
nalling pathway which involves SMAD translocation to the nucleus
and consequent transcriptional regulation. In further support of this
we have shown that activation of TGFβ is increased in response to
mechanical load and that activation rather than synthesis of TGFβ is
important in the mechanical regulation we observed. We therefore
hypothesise that application of 5% strain at 1 Hz in our model induces
TGFβ activation and subsequent signalling.Acknowledgements
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